The U.S.-based National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for CML suggest that NGS using a myeloid mutation panel should be considered for patients who present in advanced disease phases or have disease progression to advanced phases with no identifiable BCR::ABL1 kinase domain mutation [4]. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.